GLOBUS MEDICAL INC

Listed Company

GMEDCIK 0001237831NYSELarge AcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$2.94B

Net Income

$537.87M

Total Assets

$5.30B

Equity

$4.57B

Shares Out

135.25M

Op. Cash Flow

$753.45M

Business

GLOBUS MEDICAL INC develops and commercializes medical devices and healthcare solutions to improve quality of life for patients with musculoskeletal disorders. The company offers implantable devices, biologics, surgical instruments, intraoperative neuromonitoring services, and imaging, navigation and robotic systems to support spine, orthopedic trauma, hip and knee, and neurosurgical procedures. Globus organizes its offerings into two primary categories—Musculoskeletal Solutions and Enabling Technologies—covering implants, instruments, biologics, software, and robotic/navigation platforms. It sells primarily in the U.S. through a direct sales force and exclusive distributors and also distributes internationally via direct representatives and exclusive international distributors.

Summary from filing dated 2025-02-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	2,939	2,519	1,568	1,023	958
Cost of sales (exclusive of amortization of intangibles)	958	1,035	548	264	239
Research and development	147	164	124	73	97
Selling, general and administrative	1,178	981	644	432	408
Amortization of intangibles	118	119	51	18	19
Acquisition-related costs	42	30	68	6	17
Restructuring costs	15	24	0	—	—
Operating income/(loss)	480	166	133	228	172
Interest income/(expense), net	7	−4	20	—	—
Foreign currency transaction gain/(loss)	−3	−43	14	−1	−1
Bargain purchase gain	118	0	0	—	—
Other income/(expense)	3	2	−2	2	8
Total other income/(expense), net	125	−45	32	15	—
Income/(loss) before income taxes	605	121	165	243	180
Income tax provision/(benefit)	67	18	43	53	31
Net income/(loss)	538	103	123	190	149
Unrealized gain/(loss) on marketable securities	448,000	2	13	−14	−6
Foreign currency translation gain/(loss)	22	2	1	−4	−5
Total other comprehensive income/(loss), net of tax	22	3	14	−18	−11
Comprehensive income/(loss)	560	106	137	172	138
Basic (in USD per share)	3.98	0.76	1.09	1.89	1.48
Diluted (in USD per share)	3.92	0.75	1.07	1.85	1.44
Basic (in shares)	135	136	113	100	101
Diluted (in shares)	137	138	115	103	104

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-09-30
Cash and cash equivalents	526	784	—	—	—
Short-term marketable securities	31	106	50	296	—
Accounts receivable, net of allowances of $33,434 and $15,505, respectively	679	558	503	213	—
Inventories	759	659	848	299	—
Prepaid expenses and other current assets	65	50	45	21	—
Income taxes receivable	65	21	2	4	—
Total current assets	2,126	2,177	1,915	983	—
Property and equipment, net	564	562	587	244	—
Operating lease right of use assets	64	50	60	6	—
Long-term marketable securities	72	66	75	496	—
Intangible assets, net	745	795	925	64	—
Goodwill	1,435	1,432	1,435	197	—
Other assets	79	75	79	37	—
Deferred income taxes	218	94	11	49	—
Total assets	5,303	5,252	5,086	2,076	—
Accounts payable	99	75	57	36	—
Accrued expenses	334	261	240	92	—
Operating lease liabilities	15	10	12	3	—
Income taxes payable	4	11	4	990,000	—
Senior convertible notes	0	443	—	—	—
Business acquisition liabilities	20	34	61	13	—
Deferred revenue	28	22	—	—	—
Total current liabilities	498	856	392	159	—
Business acquisition liabilities, net of current portion	82	89	78	55	—
Operating lease liabilities	104	84	91	3	—
Deferred income taxes and other tax liabilities	24	24	—	—	—
Other liabilities	21	22	25	10	—
Total liabilities	730	1,074	1,088	230	—
Commitments and contingencies (Note 15)	—	—	—	—	—
Additional paid-in capital	3,170	3,031	2,871	631	—
Accumulated other comprehensive income/(loss)	15	−7	−10	−25	—
Retained earnings	1,388	1,153	1,137	1,240	—
Total equity	4,573	4,177	3,998	1,846	1,764
Total liabilities and equity	5,303	5,252	5,086	2,076	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Acquired in-process research and development	0	13	0	150,000	34
Depreciation and amortization	277	253	146	68	70
Provision for excess and obsolete inventory	22	23	11	6	6
Amortization of acquisition accounting fair value step-up	26	242	80	—	—
Stock-based compensation expense	50	54	53	33	31
Allowance for expected credit losses	10	17	4	−1,000	1
Change in fair value of business acquisition liabilities	13	27	17	5	17
Change in deferred income taxes	19	−126	−58	−22	−18
(Gain)/loss on disposal of assets, net	13	6	2	299,000	464,000
Payment of business acquisition-related liabilities	−17	−19	−3	−3	−210,000
Net (gain)/loss from foreign currency adjustment	−13	25	−14	—	—
Accounts receivable	−52	−78	−50	−51	−26
Inventories	−18	−30	−70	−62	−12
Prepaid expenses and other assets	11	1	1	−10	−6
Accounts payable	8	18	−14	14	4
Accrued expenses and other liabilities	34	5	17	6	18
Income taxes payable/receivable	−51	−13	−408,000	−3	5
Net cash provided by/(used in) operating activities	753	521	243	178	276
Purchases of marketable securities	−108	−114	−101	—	—
Maturities of marketable securities	64	59	240	312	228
Sales of marketable securities	116	12	538	102	110
Purchases of property and equipment	−165	−115	−78	−74	−57
Acquisition of businesses, net of cash acquired and purchases of intangible and other assets	−253	−18	−296	−31	−34
Acquisition of intangible assets	−10	0	0	—	—
Net cash provided by/(used in) investing activities	−355	−176	303	−110	−376
Payment of business acquisition-related liabilities	−16	−46	−8	−7	−9
Net proceeds from exercise of stock options	90	110	12	42	63
Payments related to tax withholdings for share-based compensation	−3	−7	−11	—	—
Repurchase of common stock	−300	−86	−226	−144	—
Repayment of senior convertible notes	−450	0	0	—	—
Net cash provided by/(used in) financing activities	−679	−28	−232	−110	54
Effect of foreign exchange rates on cash	22	255,000	2	−747,000	−810,000
Net increase/(decrease) in cash and cash equivalents	−258	317	317	−43	−46
Income taxes paid, net	99	159	101	78	45
Equity issued in conjunction with the NuVasive Merger	0	0	2,154	—	—
Accrued purchases of property and equipment	13	9	7	7	5
Federal	65	—	—	—	—
State	9	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro